Shares in Novo Nordisk and Eli Lilly and Company rose after early data suggested that weight-loss pills could significantly expand the global obesity treatment market, rather than simply replace injectable drugs.

Amazon has officially stepped deeper into the booming weight-loss drug market, launching a new GLP-1 treatment program designed to make obesity care faster, more convenient, and more accessible for patients.

Novo Nordisk is turning to artificial intelligence to accelerate drug development, announcing a major partnership with OpenAI as competition intensifies in the booming weight-loss market.

Novo Nordisk is launching discounted subscription plans for its weight-loss drug Wegovy in the United States, as competition intensifies in the fast-growing obesity treatment market.

At least six Indian pharmaceutical companies have introduced low-cost versions of Novo Nordisk’s (Novo Nordisk) blockbuster diabetes drug Ozempic and weight-loss medication Wegovy over the weekend, offering treatment at prices up to 70% lower than the original.

Danish drugmaker Novo Nordisk plans to sell its obesity treatments through the platform of Hims & Hers Health, ending a dispute between the two firms that recently escalated into a legal battle.

Swiss pharmaceutical giant Roche is targeting a double-digit market share in the fast-growing global weight-loss drug sector, as it looks to narrow the gap with Danish rival Novo Nordisk.

Novo Nordisk announced Tuesday that its experimental obesity treatment UBT251, a triple agonist targeting the GLP-1, GIP and glucagon receptors, delivered a statistically significant mean weight loss of up to 19.7% after 24 weeks in a clinical trial.